Human studies were, therefore, conducted in patients with several inflammatory bowel diseases [12] and cancers [13,14], demonstrating the ability of labeled IL2 to quantify the presence of CD25+ cells (IL2R) and to monitor therapeutic efficacy. Here, IL2RA is linked to inflammatory bowel disease.